Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

Bobes, Julio; Rejas, Javier; García-García, Margarida; Rico‐Villademoros, Fernando; García-Portilla, María Paz; Pinilla, Inmaculada; Hernández, Gonzalo

doi:10.1016/s0920-9964(02)00431-0

Cited by 112 publications

(67 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other than the change in antipsychotic medication, there were no other psychosocial or pharmacologic interventions that were part of the protocol, suggesting that changes in weight, BMI, and lipid levels are likely to be related to the change in antipsychotic medication. The change in weight and lipid levels associated with the three pre-switch medication regimens studied are consistent with the published literature on the rank order of relative risks these agents pose for weight gain and adverse effects on metabolic variables (Newcomer, 2005;Arato et al, 2002;Bobes et al, 2003;McIntyre et al, 2003).…”

Section: Discussionsupporting

confidence: 84%

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone

Weiden

Newcomer

Loebel

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to ziprasidone, three 52-week, open-label extension studies of ziprasidone in outpatients (N ¼ 185) with schizophrenia or schizoaffective disorder successfully completing one of three, 6-week switch studies were carried out. Pre-switch treatment consisted of risperidone (n ¼ 43), olanzapine (n ¼ 71), or conventional antipsychotic agents (n ¼ 71). The maximum length of exposure to ziprasidone was 58 weeks. Nonfasting total cholesterol and triglyceride levels were obtained at baseline and at weeks 6, 19, 32, 45, and 58. Weight was measured at baseline and during each follow-up visit; height was recorded at baseline for the purpose of body mass index (BMI) calculation. Efficacy measures included the Positive and Negative Syndrome Scale and Clinical Global ImpressionFSeverity scale which were obtained at baseline and major follow-up points. Clinically significant sustained improvements in weight, BMI, total cholesterol, and triglyceride levels were observed among patients switched to ziprasidone from risperidone or olanzapine. Switching from conventional antipsychotics was not associated with significant changes in weight and lipid parameters. Mean reductions in weight from baseline to study endpoint were 9.8 kg (po0.001) and 6.9 kg (po0.005) for patients previously treated with olanzapine and risperidone, respectively. These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids.

show abstract

Section: Discussionsupporting

confidence: 84%

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone

Weiden

Newcomer

Loebel

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Also, the observed SWG among our patients (reaching 63.3% after 2 months and 67% of the patients after 12 months) was considerably higher compared with previously published data concerning both short-and long-term use of olanzapine that point to a SWG (≥7%) affecting 15-50% of patients [Bobes et al 2003;Jaton et al 2003;Kinon et al 2005]. …”

Section: Discussioncontrasting

confidence: 68%

Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up

Balbão

Hallak

Nunes

et al. 2013

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Objective: Olanzapine is an atypical antipsychotic drug used to treat schizophrenia. Some of the adverse effects related to its use are obesity, hyperlipidemia, type 2 diabetes and hypertension, which may result in development of metabolic syndrome. This study aimed to investigate a possible increase in some anthropometric and biochemical parameters, and the existence of any correlation between them in Brazilian patients with schizophrenia treated with olanzapine in the mid term. Methods: Thirty subjects with schizophrenia were evaluated, 16 women and 14 men, aged between 18 and 47 years. All patients underwent blood collection and anthropometric measurements at four different times during 12 months of follow up; thus each patient was his or her own control. Results: Evaluation of some anthropometric measurements showed significant differences when comparing the mean values obtained in each of the different data collection times (p < 0.05). However, the biochemical indicators of development of metabolic syndrome measured in our study did not show the same rate of increment, with only the total cholesterol and glucose levels presenting statistically significant changes (p < 0.05), but without the same magnitude of weight change. Conclusion:We conclude that medium-term treatment with olanzapine promoted a substantial weight gain and increased visceral fat, while the metabolic profile did not show the same magnitude of change, suggesting a dissociation between weight gain and blood parameters, despite the severe weight gain observed among subjects evaluated.

show abstract

“…[22][23][24][25][26][27][28] However, the contribution of other variables including first-generation antipsychotics (FGA), mood stabilisers and antidepressants in the development of metabolic disorders has also been recognised. [29][30][31][32][33][34] Unmodifiable risk factors (age, ethnicity, gender and family history) and modifiable ones (level of functioning, smoking history, dietary intake and obesity) in psychiatric patients have also been associated with metabolic disorders.…”

Section: Introductionmentioning

confidence: 99%

The prevalence of metabolic syndrome and its associated factors in long-term patients in a specialist psychiatric hospital in South Africa

et al. 2013

View full text Add to dashboard Cite

Objective: The aims of this study were to determine the prevalence of metabolic disorders in long-term psychiatric patients, and the relationship between known risk factors and these metabolic disorders. Method: All psychiatric in-patients ≥18 years, who had been admitted ≥six months were invited to participate. Eighty-four patients participated. They were interviewed, examined, measured and blood tests conducted to determine several demographic and clinical variables including age, gender, weight, blood pressure and fasting blood glucose. Results: The prevalence of the metabolic disorders were: metabolic syndrome 32%, hypertension 32%, diabetes mellitus 8%, cholesterol dyslipidaemia 32%, triglyceride dyslipidaemia 29%, low density lipoprotein (LDL) dyslipidaemia 50%, overweight 37%, and obesity 24%. Black African and female patients were more likely to have metabolic syndrome. Female patients were more likely to have cholesterol dyslipidaemia and obesity. Hypertension was associated with age. Ninety-six percent of patients with dyslipidaemia were newly diagnosed during the study. Three out of the seven previously diagnosed diabetic patients had raised fasting blood glucose levels. Conclusion: The prevalence of metabolic syndrome falls towards the lower limits of the expected prevalence rate. Race and gender showed a moderate statistical association with metabolic syndrome. There is a lack of screening for dyslipidaemia in this setting. Diabetic patients should be referred to specialist diabetic clinics for better monitoring and control. developing countries. 20,21 Therefore, the first aim of the study was to determine the local prevalence of these metabolic disorders in long-term psychiatric patients.Many studies like CATIE have found a significant association between some second-generation antipsychotics (SGA) and weight gain, diabetes mellitus and dyslipidaemia. [22][23][24][25][26][27][28] However, the contribution of other variables including first-generation antipsychotics (FGA), mood stabilisers and antidepressants in the development of metabolic disorders has also been recognised. [29][30][31][32][33][34] Unmodifiable risk factors (age, ethnicity, gender and family history) and modifiable ones (level of functioning, smoking history, dietary intake and obesity) in psychiatric patients have also been associated with metabolic disorders. [35][36][37] Therefore, the second aim of the study was to determine whether these risk factors could be associated with metabolic disorders in long-term psychiatric patients.Although screening guidelines for these disorders have been recommended due to the significance of metabolic disorders in causing CVD, the guidelines are still not widely applied, even in developed countries. 38,39 Clinicians tend to rely on a patient's presentation of worrying symptoms/signs or in the case of inpatients, routine monthly blood pressure checking before investigating or treating these disorders. As a result, opportunities to detect and treat metabolic disorders may be missed. The...

show abstract

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

Cited by 112 publications

References 33 publications

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone

Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up

The prevalence of metabolic syndrome and its associated factors in long-term patients in a specialist psychiatric hospital in South Africa

Contact Info

Product

Resources

About